Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T14:40:46.537Z.
Calculation as of: 2026-10-06T14:40:46.537Z.
Quote observation: 2026-10-06T14:40:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f9f7ef7d03019e78f4201474ef0c74f9c2a497de6c29d743f28e52983e243880
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2024-04-10.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
EV/EBIT RATIO AVG TTM
N/A
EV/EBIT RATIO AVG 3Y
N/A
EV/EBIT RATIO AVG 5Y
N/A
EV/EBIT RATIO AVG 10Y
N/A
EV/EBIT RATIO AVG 15Y
N/A
EV/EBIT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$3.03B
EV/EBIT Ratio
N/A
TTM Avg
142.94x
3Y Avg
142.94x
5Y Avg
142.94x
Market Cap
$3.05B
EV/EBIT Ratio
91.27x
TTM Avg
650.30x
3Y Avg
650.30x
5Y Avg
650.30x
Market Cap
$2.79B
EV/EBIT Ratio
39.01x
TTM Avg
46.98x
3Y Avg
64.49x
5Y Avg
64.49x
Market Cap
$2.78B
EV/EBIT Ratio
193.39x
TTM Avg
169.00x
3Y Avg
169.00x
5Y Avg
169.00x
Market Cap
$2.69B
EV/EBIT Ratio
14.14x
TTM Avg
12.70x
3Y Avg
46.55x
5Y Avg
42.04x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. (AMLX) | $3.02B | N/A | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.03B | N/A | 142.94x | 142.94x | 142.94x |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.05B | 91.27x | 650.30x | 650.30x | 650.30x |
| Enliven Therapeutics, Inc. (ELVN)vs › | $2.96B | N/A | N/A | N/A | N/A |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.83B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.79B | 39.01x | 46.98x | 64.49x | 64.49x |
| AtriCure, Inc. (ATRC)vs › | $2.78B | 193.39x | 169.00x | 169.00x | 169.00x |
| Neogen Corporation (NEOG)vs › | $2.71B | N/A | 57.78x | 87.55x | 74.52x |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 14.14x | 12.70x | 46.55x | 42.04x |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.68B | 14.98x | 12.41x | 11.52x | 10.90x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBIT RATIO |
|---|---|
| 2024-04-10 | 0.11x |
| 2024-04-09 | 0.48x |
| 2024-04-08 | 0.52x |
| 2024-04-05 | 0.40x |
| 2024-04-04 | 0.38x |
| 2024-04-03 | 0.41x |
| 2024-04-02 | 0.40x |
| 2024-04-01 | 0.56x |
| 2024-03-28 | 0.79x |
| 2024-03-27 | 0.86x |
| 2024-03-26 | 0.61x |
| 2024-03-25 | 0.56x |
| 2024-03-22 | 0.61x |
| 2024-03-21 | 0.84x |
| 2024-03-20 | 1.02x |
| 2024-03-19 | 0.95x |
| 2024-03-18 | 0.82x |
| 2024-03-15 | 1.50x |
| 2024-03-14 | 1.38x |
| 2024-03-13 | 1.86x |
| 2024-03-12 | 1.86x |
| 2024-03-11 | 2.50x |
| 2024-03-08 | 1.71x |
| 2024-03-07 | 29.55x |
| 2024-03-06 | 29.70x |
| 2024-03-05 | 29.34x |
| 2024-03-04 | 29.86x |
| 2024-03-01 | 29.09x |
| 2024-02-29 | 29.34x |
| 2024-02-28 | 30.62x |
| 2024-02-27 | 29.61x |
| 2024-02-26 | 27.04x |
| 2024-02-23 | 27.20x |
